TNF and rheumatoid arthritis: Anti-TNF therapy was approved by the U. S. Food & Drug Administration (FDA) in 1998, and currently, it is efficiently administered as a treatment for diverse inflammatory processes like rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, Crohn ́s disease, plaque psoriasis, among others [15,76,85,86].